세계의 신경아세포종 치료제 시장 규모 조사 : 유형별, 투여 경로별, 유통 채널별, 지역별, 예측(2022-2032년)

Global Neuroblastoma Drugs Market is valued approximately USD 740 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rising shift towards personalized medicine and targeted therapies is a key trend for the Global Neuroblastoma Drugs Market. Drug developers are concentrating more on creating medications that specifically target genetic abnormalities or biological processes associated with neuroblastoma. This method reduces adverse effects and enhances patient outcomes by enabling more focused and efficient therapy.

In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.

The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.

Major market player included in this report are:

• Recordati Group
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Y-mabs Therapeutics, Inc.
• MacroGenics Inc.
• AstraZeneca plc
• United Therapeutics Corporation
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Cellectar Biosciences, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

• Chemotherapy
• Immunotherapy
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Online
• Offline

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Neuroblastoma Drugs Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Type
  • 2.3.2. By Route of Administration
  • 2.3.3. By Distribution Channel
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Neuroblastoma Drugs Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Neuroblastoma Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032

• 5.1. Chemotherapy
• 5.2. Immunotherapy
• 5.3. Others

Chapter 6. Global Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Oral
• 6.2. Injectable

Chapter 7. Global Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032

• 7.1. Online
• 7.2. Offline

Chapter 8. Global Neuroblastoma Drugs Market Size & Forecasts by Region 2022-2032

• 8.1. North America Neuroblastoma Drugs Market
  • 8.1.1. U.S. Neuroblastoma Drugs Market
    • 8.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Neuroblastoma Drugs Market
• 8.2. Europe Neuroblastoma Drugs Market
  • 8.2.1. U.K. Neuroblastoma Drugs Market
  • 8.2.2. Germany Neuroblastoma Drugs Market
  • 8.2.3. France Neuroblastoma Drugs Market
  • 8.2.4. Spain Neuroblastoma Drugs Market
  • 8.2.5. Italy Neuroblastoma Drugs Market
  • 8.2.6. Rest of Europe Neuroblastoma Drugs Market
• 8.3. Asia-Pacific Neuroblastoma Drugs Market
  • 8.3.1. China Neuroblastoma Drugs Market
  • 8.3.2. India Neuroblastoma Drugs Market
  • 8.3.3. Japan Neuroblastoma Drugs Market
  • 8.3.4. Australia Neuroblastoma Drugs Market
  • 8.3.5. South Korea Neuroblastoma Drugs Market
  • 8.3.6. Rest of Asia Pacific Neuroblastoma Drugs Market
• 8.4. Latin America Neuroblastoma Drugs Market
  • 8.4.1. Brazil Neuroblastoma Drugs Market
  • 8.4.2. Mexico Neuroblastoma Drugs Market
  • 8.4.3. Rest of Latin America Neuroblastoma Drugs Market
• 8.5. Middle East & Africa Neuroblastoma Drugs Market
  • 8.5.1. Saudi Arabia Neuroblastoma Drugs Market
  • 8.5.2. South Africa Neuroblastoma Drugs Market
  • 8.5.3. Rest of Middle East & Africa Neuroblastoma Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Recordati Group
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Eli Lilly and Company
  • 9.3.3. Bristol-Myers Squibb Company
  • 9.3.4. Y-mabs Therapeutics, Inc.
  • 9.3.5. MacroGenics Inc.
  • 9.3.6. AstraZeneca plc
  • 9.3.7. United Therapeutics Corporation
  • 9.3.8. Pfizer Inc.
  • 9.3.9. Teva Pharmaceutical Industries Ltd.
  • 9.3.10. Cellectar Biosciences, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes